MedTrace Logo

Reconstitution of a Human Immune System in a Patient Derived Xenograft (PDX) Model of Genitourinary (GU) Cancers

NCT03134027 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 3

Last updated 2024-07-18

No results posted yet for this study

Summary

The objective of this study is to obtain human blood CD34+ hematopoietic stem/progenitor cells (HSPCs) to reconstitute a match human immune system in our PDX model. The hypothesis is that by using matched leukocytes and PDX from the same patient, rejection of the PDX by the host immune system will not be observed and therefore a preclinical model to study immunotherapy can be developed to study, understand and improve upon our current therapies. HSPCs will be collected from bone marrow aspirate obtained from a bone marrow biopsy.

The secondary objective is to use patient tumor biopsy samples or circulating tumor cell samples to develop additional preclinical models of GU cancers, particularly prostate cancer, that are clinically relevant by generating additional PDXs.

Conditions

Interventions

PROCEDURE

Bone marrow biopsy

Subjects will undergo a bone marrow biopsy to obtain aspirate for stem cell collection.

PROCEDURE

Tumor biopsy

Subjects will undergo a tumor biopsy to obtain tissue for generation of a PDX.

Sponsors & Collaborators

Principal Investigators

  • Andrew Armstrong, MD, ScM · Duke Cancer Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-10-19
Primary Completion
2018-05-09
Completion
2018-05-09

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03134027 on ClinicalTrials.gov